Omnicell, Inc. $OMCL Stock Holdings Lifted by AlphaQuest LLC

AlphaQuest LLC lifted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 388.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 24,231 shares of the company’s stock after buying an additional 19,270 shares during the period. AlphaQuest LLC owned 0.05% of Omnicell worth $738,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of OMCL. WINTON GROUP Ltd bought a new stake in Omnicell in the second quarter valued at $2,692,000. State of Alaska Department of Revenue increased its holdings in shares of Omnicell by 8.7% in the 2nd quarter. State of Alaska Department of Revenue now owns 27,906 shares of the company’s stock worth $819,000 after acquiring an additional 2,242 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in Omnicell by 1.3% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock valued at $41,854,000 after purchasing an additional 17,680 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new stake in Omnicell in the 2nd quarter valued at about $2,476,000. Finally, Assenagon Asset Management S.A. boosted its stake in Omnicell by 1,316.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock valued at $4,284,000 after purchasing an additional 130,742 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of Omnicell stock opened at $46.04 on Wednesday. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.00. The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. The stock has a market cap of $2.07 billion, a PE ratio of 107.07, a price-to-earnings-growth ratio of 5.19 and a beta of 0.78. The company’s 50-day moving average price is $45.96 and its two-hundred day moving average price is $36.84.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. UBS Group set a $53.00 price target on shares of Omnicell in a research note on Friday, January 16th. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. Wells Fargo & Company lifted their target price on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research note on Thursday, January 22nd. Finally, KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a research note on Wednesday, January 7th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $50.00.

Insider Buying and Selling

In related news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares in the company, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.52% of the stock is currently owned by corporate insiders.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.